12:00 AM
Sep 12, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Viaskin rPT: Phase I started

DBV began a double-blind, placebo-controlled, dose-escalation, Swiss Phase I trial to evaluate two 48-hour applications of 25 and 50 ug Viaskin rPT given 2 weeks apart in about 60 healthy adults. Subjects will receive 1...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >